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Summary 
Background: Eosinophil cationic protein (ECP) 
was reported previously to be involved in allergic 
inflammation with cytotoxic activity. On the 
other hand, recent studies showed that ECP did 
not induce cell death but inhibited the growth of 
cancer-derived cells. Our previous study 
indicated that human ECP enhanced differentiation 
of rat neonatal cardiomyocytes and stress fiber 
formation in Balb/c 3T3 mouse fibroblasts, while 
the effects of human ECP on human fibroblasts 
are unknown. 
Objective: The present study was performed to 
determine the effects of human ECP on cytokine 
expression in human fibroblasts by protein 
array. 
Methods: The effects of recombinant human ECP 
(rhECP) on normal human dermal fibroblasts 
(NHDF) were examined by assaying cell growth. 
Furthermore, cytokine expression of NHDF 
stimulated by ECP, which could influence cell 
growth, was evaluated by protein array. 
 
 
 
 
 
 
 
 
 
 
 
 
Results: ECP was not cytotoxic but enhanced the 
growth of NHDF. The peak rhECP concentration 
that enhanced the cell counts by 1.56-fold was 
100 ng/mL, which was significantly different 
from cultures without ECP stimulation (ANOVA/ 
Scheffe’s test, P < 0.05). Array analyses indicated 
that ciliary neurotrophic factor (CNTF), neutrophil- 
activating peptide (NAP)-2, and neurotrophin 
(NT)-3 were significantly upregulated in NHDF 
stimulated with 100 ng/mL ECP compared to 
those without stimulation. 
Conclusion: ECP is not cytotoxic but enhances 
the growth of NHDF. CNTF, NAP-2, and NT-3 
were suggested to be involved in enhancing the 
growth of NHDF. These findings will contribute 
to determination of the role of ECP in allergic 
inflammation. (Asian Pac J Allergy Immunol 
2013;31:271-6) 
Key words: cytokine, eosinophil cationic protein, 
fibroblast, growth  
Introduction 
Eosinophil cationic protein (ECP) is one of the 
proteins released on eosinophil degranulation, and is 
generally recognized as being involved in allergic 
inflammation with cytotoxic activity. This 
cytotoxicity is mainly explained as an antiparasitic 
and bactericidal activity in infectious diseases. 
However, ECP has also been reported to be 
cytotoxic toward host cells, e.g., the tracheal 
epithelium.1  
On the other hand, recent studies showed that 
ECP has a broad impact on cell functions. ECP was 
reported to show neurotoxicity
2
 and apoptotic 
effects on several eukaryotic cell lines,3 while its did 
not induce cell death but inhibited the growth of 
cancer-derived cells.4 Furthermore, human ECP 
enhanced differentiation of rat neonatal 
cardiomyocytes and stress fiber formation in Balb/c 
3T3 mouse fibroblasts,
5
 while the effects of human 
From 1. Department of Pathophysiology - Periodontal 
Science, Okayama University Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, Okayama, Japan 
2. Division of Hospital Dentistry, Central Clinical 
Department, Okayama University Hospital, Okayama, 
Japan 
3. Division of Dermatology, National Sanatorium 
Nagashima-Aiseien, Okayama, Japan 
4. Department of Medical and Bioengineering Science, 
Okayama University Graduate School of Natural Science 
and Technology, Okayama, Japan 
Corresponding author: Yoshihiko Soga 
E-mail:  y_soga@md.okayama-u.ac.jp 
Submitted date: 14/5/2012 
Accepted date: 25/12/2012 
 
Downloaded from http://apjai.digitaljo urnals.org. For personal use only. No other uses without permission.
Asian Pac J Allergy Immunol 2013;31:271-6 DOI 10.12932/AP0287.31.4.2013 
 
272 
 
ECP on human fibroblasts are unknown. Despite 
their usefulness in determination of eosinophil 
physiology in vivo, murine models differ from 
humans in several major respects.6 For example, 
airway mucosal eosinophils in allergen-challenged 
mice lack signs of degranulation 7. Thus, the role of 
human ECP could be different from that in rodents. 
Therefore, it is important to evaluate the effects of 
human ECP on human fibroblasts. ECP is detected 
in allergic inflammatory lesions, and is widely used 
as a biomarker for the activity of allergic 
inflammation. Thus, ECP is generally considered to 
be involved in allergic pathology. Evaluation of 
cytokine expression in human fibroblasts stimulated 
by ECP could reveal the role of ECP in allergic 
lesions. However, little information is available 
regarding cytokine expression of human fibroblasts 
stimulated by ECP. One study showed that ECP 
stimulates transforming growth factor (TGF)-β1 
release by human lung fibroblasts in vitro,8 although 
the cytokine production profile from fibroblasts 
stimulated by ECP has not been determined in 
detail. 
In the present study, we examined the effects of 
recombinant human ECP (rhECP) on normal human 
dermal fibroblasts (NHDF) by assay for cell growth. 
Furthermore, cytokine expression of NHDF 
stimulated by ECP, which could influence cell 
growth, was evaluated by protein array. 
Methods  
Recombinant human ECP 
Recombinant human ECP (rhECP) in mature 
form without the secretion signal peptide was 
expressed in bacteria and prepared as described 
previously.
9
 Briefly, human ECP cDNA was 
isolated and expressed in an Escherichia coli T7 
expression system. Purified rhECP was assessed for 
RNase activity on yeast RNA by the perchloric acid 
precipitation method
10
 and for bactericidal activity.
11
 
The amino acid sequence, CD spectra, and apparent 
molecular mass on SDS-PAGE were confirmed. No 
endotoxin was detected by limulus test. rhECP was 
of sufficiently high purity that crystals could be 
obtained, and these were used to determine the 3D 
structure at high resolution.
9
 Therefore, this 
preparation should not include any contaminants 
derived from bacterial cells. 
 
Culture of NHDF 
Commercially available adult NHDF (Lonza 
Walkersville, Inc., Walkersville, MD) were maintained 
in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) 
and 10 µg/mL gentamycin at 37°C under a 
humidified 5% CO2 atmosphere. All in vitro studies 
using NHDF were performed between passages 5 
and 9. 
 
Microscopic observation and cell counts of 
NHDF stimulated with rhECP 
NHDF were plated into 8-well chamber slides 
(Lab-Tek™ Chambered Coverglass; Nalge-Nunc, 
Rochester, NY) with DMEM containing 10% FBS 
and 10 µg/mL gentamycin at 5.0×10
3
 cells/well. 
After 24 h, the medium was changed to DMEM 
containing 0.5% FBS without gentamycin. After a 
further 24 h, cells were stimulated with rhECP (0 – 
10 µg/mL) for 24 h. The cells were stained with 
hematoxylin-eosin, and microscopic observation of 
NHDF with or without rhECP (0 – 10 µg/mL) 
stimulation was performed. Furthermore, the 
number of NHDF cells was counted at a 
magnification of ×100. Five separate fields from a 
single well were counted, and five separate wells 
were used for each rhECP concentration group. 
Averages and standard deviations were calculated 
from three independent experiments.  
Cytokine measurements 
NHDF were plated into 6-well multiple well 
plates (Corning, Lowell, MA) with DMEM 
containing 10% FBS and 10 µg/mL gentamycin at 
1.0×10
5
 cells/well. After 24 h, the medium was 
changed to DMEM containing 0.5% FBS without 
gentamycin. After a further 24 h, cells were 
stimulated with or without 100 ng/mL rhECP for 24 
h.  
Culture supernatants were obtained, and cytokine 
measurements were performed by Human Cytokine 
Antibody Array C series 1000 (Ray Biotech Inc, 
Norcross, GA), consisting of 120 different cytokine 
and chemokine antibodies spotted in duplicate onto 
a membrane according to the manufacturer’s 
instructions. The array was exposed to film 
(Amersham Biosciences, Buckinghamshire, UK) 
and the intensity of signals was detected using 
ImageJ software (NIH, Bethesda, MD). The relative 
intensity levels of the cytokines were normalized 
with reference to the amounts present on the positive 
control in each membrane based on the average of 
cytokine spot intensity levels divided by the average 
of the positive control spot intensity levels and are 
shown as percentages. The sensitivities of the 
cytokines examined are provided on the manufacturer’s 
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website (http://www.raybiotech.com/Resources.asp? 
m=6). Average and standard deviations were 
calculated from three independent experiments. 
Statistical analysis 
All statistical analyses were performed using 
SPSS statistical software version 13.0 (SPSS, 
Chicago, IL). The cell counts for NHDF stimulated 
with each concentration of ECP were compared to 
those without ECP stimulation using 
ANOVA/Scheffe’s test. The results of Cytokine 
Antibody Array with and without ECP stimulation 
were compared using Welch’s t test. In all analyses, 
P < 0.05 was taken to indicate statistical 
significance. 
Results 
Microscopic observation and cell counts of NHDF 
stimulated with rhECP  
The results of microscopic observation are 
shown in Figure. 1. ECP was not cytotoxic toward 
NHDF, but rather enhanced the growth of these 
cells. Cell counts of NHDF stimulated with rhECP 
are shown in Figure. 2. A dose-dependent increase 
in cell count was observed. The peak rhECP 
concentration that enhanced the cell counts by 1.56-
fold was 100 ng/mL, which was significantly 
different from cultures without ECP stimulation 
(ANOVA/Scheffe’s test, P < 0.05). 
Cytokine expression in NHDF stimulated with 
rhECP 
The relative cytokine levels released from NHDF 
with or without rhECP stimulation are summarized 
in Table 1. The array analyses indicated that ciliary 
neurotrophic factor (CNTF), neutrophil-activating 
peptide (NAP)-2, and neurotrophin (NT)-3 were 
significantly upregulated in NHDF stimulated with 
rhECP compared to those without stimulation 
(Welch’s t test, P < 0.05). 
Discussion 
The results of the present study indicated that 
ECP is not cytotoxic but enhances the growth of 
NHDF, which was consistent with our previous 
observations in Balb/c 3T3 mouse fibroblasts. The 
peak rhECP concentration that enhanced the cell 
count was 100 ng/mL, and therefore we performed 
subsequent cytokine expression analysis of NHDF 
by protein array at this rhECP concentration. The 
results of array analyses indicated that CNTF, NAP-
2, and NT-3 were significantly upregulated in
 
 
 
 
 
 
Figure 1. Microscopic observation (×100) of NHDF with 
or without rhECP (10
-2 – 103 ng/mL) stimulation for 24 h. 
NHDF were stained with hematoxylin-eosin. 
 
 
NHDF with ECP stimulation compared to 
unstimulated controls.  
CNTF is a member of IL-6 cytokine family, 
which promotes the maintenance, differentiation, 
and/or survival of a variety of neurons within the 
nervous system.
12
 In addition to the effects on the 
nervous system, CNTF also acts on the immune 
system. Interestingly, it has been reported that 
CNTF enhances IgE production by B cells from 
atopic patients.
13
 CNTF derived from NHDF by 
ECP stimulation may contribute to the elevation of 
IgE level in allergic inflammation. 
NAP-2 is the chemotactically most active form 
of chemokine (C-X-C motif) ligand (CXCL)7. 
CXCL7 is the most abundant of the chemokines 
stored and secreted by platelets,
14
 while our results 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cell counts of NHDF with or without rhECP 
(10
-2 – 103 ng/mL) stimulation for 24 h. rhECP 
concentrations in the range 10
-1 – 103 ng/mL significantly 
enhanced the number of NHDF cells compared to 
unstimulated controls (*P < 0.05, ANOVA/Fisher’s 
PLSD). The peak rhECP concentration that enhanced the 
cell count by 1.56-fold was 100 ng/mL. 
 
 
* 
* 
* * 
* 
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Table 1. Relative cytokine levels 
 
Cytokine 
Relative cytokine levels 
to positive control (%) 
Fold 
increase 
ECP (–) ECP (+) 
Angiogenin 10.0±4.6 13.3±9.4 1.33 
BDNF 12.0±7.4 12.1±3.3 1.01 
BLC 4.4±1.8 5.5±2.6 1.26 
BMP-4 9.8±6.0 10.2±4.2 1.04 
BMP-6 6.9±1.8 8.3±1.0 1.2 
CKb8-1 11.4±4.4 14.6±2.4 1.28 
CNTF 7.4±0.5 8.9±0.5* 1.21 
EGF 19.0±5.4 19.6±1.4 1.03 
Eotaxin 11.7±10.1 7.6±1.6 0.65 
Eotaxin-2 11.5±2.2 8.8±4.8 0.77 
Eotaxin-3 6.6±2.5 5.4±3.0 0.82 
FGF-6 11.0±4.9 10.3±4.4 0.94 
FGF-7 7.9±6.7 8.5±5.6 1.06 
Fit-3 Ligand 4.6±2.9 6.4±3.9 1.4 
Fractalkine 5.7±3.3 6.5±2.5 1.15 
GCP-2 5.7±2.8 5.6±2.3 0.98 
GDNF 8.8±3.0 9.2±3.2 1.04 
GM-CSF 2.2±0.9 2.1±1.3 0.95 
I-309 6.8±1.3 7.1±1.7 1.05 
IFN-g 6.1±0.1 7.6±1.2 1.25 
IGFBP-1 4.8±2.1 6.9±3.8 1.43 
IGFBP-2 16.6±4.6 16.6±3.9 1 
IGFBP-4 19.4±25.9 17.2±20.3 0.89 
IGF-1 4.8±3.2 3.5±1.6 0.73 
IL-10 5.4±0.4 3.5±1.0 0.64 
IL-13 1.7±1.0 1.5±1.6 0.89 
IL-15 7.4±5.1 7.6±4.8 1.02 
IL-16 5.1±3.4 6.0±3.0 1.17 
IL-1α 5.7±2.2 7.6±4.8 1.34 
IL-1β 5.9±1.4 5.9±1.9 1 
IL-1ra 14.6±2.6 12.8±3.2 0.88 
IL-2 4.3±2.3 4.0±1.5 0.94 
IL-3 5.6±1.8 5.9±1.8 1.05 
IL-4 4.3±1.5 5.0±1.8 1.14 
IL-5 4.6±5.0 8.2±9.8 1.77 
IL-6 41.2±65.9 46.9±73.2 1.14 
IL-7 5.6±8.1 3.3±3.3 0.59 
LEPTIN(OB) 9.6±3.6 7.4±3.7 0.77 
LIGHT 8.0±2.7 9.3±2.8 1.16 
MCP-1 22.4±20.9 25.6±29.1 1.14 
MCP-2 5.9±4.0 6.4±3.5 1.08 
MCP-3 1.9±0.3 2.4±1.8 1.28 
MCP-4 4.3±1.0 4.6±2.2 1.06 
M-CSF 11.9±2.4 11.5±0.5 0.96 
MDC 12.2±3.7 8.8±1.4 0.72 
MIG 8.0±3.9 8.1±2.1 1.01 
MIP-1d 4.4±3.7 4.9±2.5 1.12 
MIP-3a 6.3±3.1 6.6±1.7 1.04 
NAP-2 15.0±1.0 18.9±1.4* 1.25 
NT-3 15.7±2.3 21.0±2.8* 1.34 
PARC 13.4±12.8 13.3±8.0 0.99 
PDGF-BB 7.7±2.8 5.9±4.4 0.76 
RANTES 11.6±5.2 15.1±3.8 1.3 
SCF 8.2±5.4 11.1±3.6 1.35 
SDF-1 16.1±12.1 18.6±6.0 1.16 
TARC 10.9±6.9 11.0±4.5 1.01 
TGF-b1 7.2±2.8 7.0±3.5 0.96 
TGF-b3 10.3±1.4 9.6±1.7 0.93 
TNF-a 9.8±7.0 7.9±4.4 0.81 
TNF-b 13.9±2.8 15.7±5.2 1.13 
 
    
    
Table 1. Continued 
Cytokine 
Relative cytokine levels 
to positive control (%) 
Fold 
increase 
ECP (–) ECP (+) 
Adiponectin/Acp30 5.9±3.6 5.8±4.8 0.98 
AgRP (ART) 12.4±6.5 8.9±7.6 0.72 
Angiopoletin-2 14.7±6.9 10.1±9.1 0.69 
AR (Amphiregulin) 11.3±5.2 7.7±6.6 0.68 
Axl 11.8±3.3 9.4±4.6 0.79 
bFGF 10.0±5.6 6.9±5.1 0.69 
NGF-b 8.2±4.0 5.8±3.7 0.71 
BTC 11.6±2.2 10.0±4.4 0.87 
CCL28/VIC 5.9±3.1 4.5±2.3 0.76 
CTACK/CCL27 6.5±5.4 9.9±3.3 1.52 
Dtk 9.0±8.9 9.8±5.7 1.09 
EGF-R 4.3±3.7 4.4±3.6 1.04 
ENA-78 6.9±4.3 7.7±5.2 1.11 
Fas/TNFRSF6 17.1±9.0 17.3±8.6 1.01 
FGF-4 25.6±6.3 26.9±10.5 1.05 
FGF-9 17.6±10.2 16.4±11.3 0.93 
GCSF 6.6±1.4 4.4±0.8 0.67 
GITR Ligand/TNFSF18 9.2±3.6 7.0±4.3 0.76 
GITR/TNFRF18 12.7±4.4 10.1±5.4 0.8 
GRO 34.0±5.8 30.9±5.5 0.91 
GRO-a 7.3±2.8 6.0±3.8 0.82 
HCC-4/CCL16 10.9±4.3 9.1±5.0 0.83 
HGF 9.6±5.6 13.4±12.2 1.39 
ICAM-1 7.4±5.7 10.3±5.7 1.38 
ICAM-3 5.9±4.4 6.3±4.1 1.07 
IGFBP-3 13.7±8.5 12.2±7.2 0.89 
IGFBP-6 24.3±4.7 24.0±6.9 0.99 
IGF-1sR 10.8±6.6 10.5±8.5 0.97 
IL-1R4/ST2 12.8±6.8 12.9±7.0 1.01 
IL-1sRI 8.7±5.1 7.9±5.1 0.91 
IL-11 4.2±2.3 2.9±1.4 0.7 
IL-12p40 20.4±8.0 18.5±9.0 0.91 
IL-12p70 11.8±4.4 9.2±6.8 0.78 
IL-17 5.3±2.2 3.7±2.4 0.69 
IL-2Ralpha 10.0±3.3 9.0±6.3 0.9 
IL-6sR 14.7±1.6 14.0±4.8 0.95 
IL-8 12.8±2.5 13.0±4.1 1.01 
I-TAC/CXCL11 6.7±6.0 9.5±5.7 1.41 
Lymphotactin 10.0±5.2 10.6±5.8 1.06 
MIF 18.4±6.0 18.9±8.4 1.02 
MIP-1a 13.2±6.9 13.2±8.3 1 
MIP-1b 11.0±7.0 10.7±7.2 0.97 
MIP-3b 4.1±2.7 3.5±2.5 0.85 
MSP a 19.0±9.5 18.9±8.9 1 
NT-4 10.4±3.3 9.5±4.1 0.91 
Osteoprotegerin 43.8±11.1 41.6±11.7 0.95 
ONCOSTATIN M 11.6±5.8 10.6±7.9 0.91 
PIGF 7.3±2.3 6.5±4.0 0.89 
sgp130 12.9±3.1 11.7±5.2 0.91 
sTNFRII/TNFRS1B 13.9±3.0 12.2±6.5 0.88 
sTNFRI/TNFRS1A 19.0±6.4 16.0±6.6 0.84 
TECK/CCL25 5.9±5.1 8.1±4.8 1.37 
TIMP-1 72.1±2.5 63.3±10.8 0.88 
TIMP-2 69.5±12.0 62.0±14.2 0.89 
TPO 4.7±5.3 4.4±4.0 0.94 
TRAILsR3/TNFRS10C 8.2±5.0 7.8±5.7 0.95 
TRAILR4/TNFRS10D 7.3±3.9 7.0±4.8 0.97 
uPAR 17.6±6.4 16.0±6.0 0.91 
VEGF 9.9±4.8 10.0±5.8 1.01 
VEGF-D 12.7±7.1 8.9±11.4 0.7 
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indicated that ECP stimulated NHDF to secrete one 
of the variants of CXCL7, i.e., NAP2. There are 
several known molecular variants of CXCL7, 
including platelet basic protein (PBP), connective 
tissue-activating peptide III (CTAP-III), β-
thromboglobulin (β -TG), and NAP-2.14 These 
CXCL7 variants are proteolytically derived from a 
precursor molecule (pre-platelet basic protein; pre-
PBP) encoded by the CXCL7 gene.
14
 It has been 
reported that both CTAP-III and NAP-2, as well as 
other truncated CXCL7 variants of intermediate 
size, all have the capacity to support various aspects 
of fibroblast metabolism, e.g., synthesis of matrix 
components, such as hyaluronic acid and 
glycosaminoglycans (GAGs),
15
 enhancement of 
GLUT-1 glucose transporter expression, and concomitant 
glucose uptake.
16
 Based on these previous reports, 
our results indicate a mechanism by which ECP 
stimulates NHDF to enhance their growth; i.e., 
autocrine activation of ECP stimulated NHDF via 
NAP-2 produced by themselves. 
NT-3 is a member of the neurotrophin (NT) 
family, which are growth factors originally 
described as critical trophic factors involved in the 
regulation of neuronal development, survival, and 
function, including synapse formation and plasticity. 
17
 On the other hand, elevated serum levels of NTs 
have been found in patients with various allergic 
diseases, including asthma, allergic rhinitis, and 
atopic dermatitis.17 It was reported that NTs, 
including NT-3, were produced endobronchially 
following allergen provocation, and they were 
suggested to contribute to the pathogenesis of 
asthma.18 It is not surprising that ECP induces NT-3 
production by fibroblasts.  
All three significantly upregulated molecules—
CNTF, NAP-2, and NT-3—could explain the 
involvement of ECP in allergic inflammation and 
the promotion of growth of NHDF. Indeed, while 
not particularly high (1.56-fold), the enhancement of 
cell count by ECP stimulation was observed. These 
findings regarding ECP activity suggest that ECP 
functions in fibrosis with mild promotion of allergic 
inflammation. Other molecules that were 
upregulated below the level of significance on array 
analysis may also contribute to this phenomenon in 
a cooperative manner. Our results also indicated that 
the levels of production of major proinflammatory 
cytokines, such as IL-1β, IL-6, TNF-α, etc., were 
not significantly increased by ECP stimulation. 
Taken together, these observations indicated that 
ECP is not cytotoxic and does cause a strong 
inflammatory reaction in NHDF. 
Zagai et al. reported that ECP stimulates TGF-β1 
release by human lung fibroblasts.8 However, their 
experiments were performed with ECP stimulation 
at doses of 1 – 10 µg/mL. Significant elevation of 
TGF-β1 release was observed with ECP stimulation 
at concentrations > 5 µg/mL, and was not observed 
at 1 µg/mL. Our experiment was performed with 
ECP stimulation at a dose below 1 µg/mL (i.e., 100 
ng/mL). Our observation that there was no 
significant change in TGF-β1 release from NHDF 
by ECP stimulation is not in conflict with the report 
of Zagai et al.8 
In conclusion, ECP is not cytotoxic but enhances 
the growth of NHDF. The results of array analyses 
indicated that CNTF, NAP-2, and NT-3 were 
significantly upregulated in NHDF with ECP 
stimulation compared with unstimulated controls. 
These findings could contribute to determination of 
the role of ECP in allergic inflammation. 
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